Ozempic made Novo Nordisk famous. Zepbound and Mounjaro made Eli Lilly a monster. And Wall Street still can’t decide if LLY is a rocket ship or a bubble waiting to pop. Here’s the blunt truth: Eli Lilly isn’t just riding the GLP-1 wave — it owns a massive chunk of it. And that’s why the…